関連する実験動画

Updated: Jul 11, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

耐火性コンドロサルコマの患者におけるアンロチニブとアンロチニブ単独の抗体:多センター非ランダム化第2相FLAIL- C試験

Binghao Li¹, Lu Xie², Junbo Liang³

¹Orthopaedic Oncology Services, Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China; Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou 310009, China.

Med (New York, N.Y.)

|August 29, 2025

まとめ

抗PD-1抗体とアノロチニブを併用した治療は,進行性軟骨腫の改善を示した. 分離性軟骨腫の患者は最も大きな利益を得て治療の新たな選択肢を提案しました

科学分野:

腫瘍学
免疫療法
薬理学について

背景:

非切除性軟骨腫には標準的な全身療法がない.
新規の治療戦略の調査は患者の治療結果を改善するために不可欠です

研究の目的:

抗PD-1 抗体とアロチニブによる併用療法の有効性を評価する.
進行性軟骨腫患者の治療結果を評価する.

主な方法:

非差別化または高度の従来の軟骨髄膜腫の患者を対象とした臨床試験
アンロチニブ (12 mg/ 日,1~14日,3週間に1回) をPD-1抗体 (200 mg/ 3週間に1回) と併用して投与する.
主要エンドポイント: 6ヶ月の無進行生存率 (PFSR);バイオマーカー分析が行われました.

主要な成果:

併用治療は,アロチニブ単独投与と比較して,PFSR (60. 0% vs 31. 4%) を有意に改善しました.
分離性軟骨腫患者は,客観的な応答率の改善 (33. 3% 対 9. 1%) とPFSの中央値の改善 (7. 0 対 3. 8 ヶ月) を示した.
エフェクターメモリーT細胞は,治療反応と有意に相関していた (p < 0. 001).

結論:

PD-1 抗体とアロチニブを併用した治療は,進行性軟骨腫において有望な効果を示しています.
分離性軟骨腫の患者は特にこの併用治療の恩恵を受けます.
治療の新たな基準として確立されるかもしれません

キーワード:

患者さんへの翻訳コンドロサルコマ臨床試験併用療法免疫療法

さらに関連する動画

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

関連する概念動画

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.